A new study published in medRxiv shows that incretin-based weight loss drugs like semaglutide and tirzepatide mostly reduce fat while preserving muscle strength and mobility. Data from both humans and animals revealed improved body composition and function, easing concerns about muscle loss during treatment despite minor reductions in lean mass.